Back to Browse Journals » Nature and Science of Sleep » Volume 2

Ready for takeoff? A critical review of armodafinil and modafinil for the treatment of sleepiness associated with jet lag

Authors David E McCarty

Published 17 May 2010 Volume 2010:2 Pages 85—94


Review by Single-blind

Peer reviewer comments 5

David E McCarty

Sleep Medicine Program, Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
Abstract: Jet lag syndrome (JLS) is a clinical syndrome of disrupted nocturnal sleep and daytime neurocognitive impairment which occurs in the context of rapid transmeridian travel. Many strategies for treatment of JLS exist, and include hypnotics to enhance nocturnal sleep, chronotherapeutic approaches (eg, light therapy, melatonin, or gradual schedule shifting), and alerting agents to counter daytime sleepiness. Safety concerns have prompted renewed interest in managing JLS-associated excessive daytime sleepiness (JLSAEDS). Off-label use of the newer alerting agents modafinil and armodafinil is increasing for this indication, often at the specific request of patients. In order to better evaluate the potential risks and benefits of these medications for the management of JLSAEDS, clinicians must be aware of what is known – and still not known. In this article, the pharmacology and pharmacokinetics of modafinil and armodafinil are reviewed, along with evidence for their efficacy in treating sleepiness associated with narcolepsy, obstructive sleep apnea and shift work sleep disorder. Clinical trial data for use of alerting agents in the management of JLSAEDS are limited to one three-day trial involving armodafinil, dosed in the morning to treat JLSAEDS in the setting of eastbound transmeridian travel. This study showed improvement in objective measures of daytime sleepiness at doses of 50 and 150 mg per day. However, global impression of clinical severity of symptom scores only improved on day 1 for those patients receiving 150 mg, and were otherwise not superior to placebo. Consideration for the use of modafinil or armodafinil for the treatment of sleepiness associated with JLS involves careful integration of patient-reported goals, a review of medical contraindications, and an awareness of rare adverse events. More research is needed in order to identify those who are most likely to benefit from this intervention and better define the risk-benefit ratio for this indication.

Keywords: jet lag syndrome, modafinil, armodafinil

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Nonspecific pain is a marker for hypovitaminosis D in patients undergoing evaluation for sleep disorders: a pilot study

McCarty DE, Reddy A, Keigley Q, Kim PY, Cohen S, Marino AA

Nature and Science of Sleep 2013, 5:37-42

Published Date: 9 March 2013

Readers of this article also read:

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics

Farrugia A, Noone D, Schlenkrich U, Schlenkrich S, O’Mahony B, Cassar J

Journal of Blood Medicine 2015, 6:185-195

Published Date: 15 June 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy

Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor IK, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S

Journal of Blood Medicine 2015, 6:87-92

Published Date: 20 March 2015

Romiplostim as a treatment for immune thrombocytopenia: a review

Chalmers S, Tarantino MD

Journal of Blood Medicine 2015, 6:37-44

Published Date: 19 January 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Treatment of patients with von Willebrand disease

Tuohy E, Litt E, Alikhan R

Journal of Blood Medicine 2011, 2:49-57

Published Date: 20 April 2011